Assessing Surge Capacity for Radiation Victims with Marrow Toxicity
Matthew S. Davids(Dana-Farber Cancer Institute), David M. Weinstock(Broad Institute), Nelson J. Chao(Duke University), C. Norman Coleman(Unknown), Daniel J. Weisdorf(University of Minnesota), John P. Chute(Cedars-Sinai Medical Center), Dennis L. Confer(National Marrow Donor Program), Raymond A. Hornung(National Marrow Donor Program), Cullen Case(National Marrow Donor Program)
Cited by 10
Related Papers
National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. The 2014 Diagnosis and Staging Working Group Report
|Biology of Blood and Marrow Transplantation|2014|5.4k
PI3K/AKT/mTOR signaling transduction pathway and targeted therapies in cancer
|Molecular Cancer|2023|1.9k
Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2015|1.9k
Lenalidomide after Stem-Cell Transplantation for Multiple Myeloma
|New England Journal of Medicine|2012|1.1k
Phase I First-in-Human Study of Venetoclax in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma
|Journal of Clinical Oncology|2017|752